{"id":4242,"company":{"country":"CH","currency":"USD","exchange":"SWISS EXCHANGE","ipo":"2001-05-07","marketCap":195259,"name":"Novartis AG","phone":"41613241111","outstanding":1956.49,"symbol":"NVS","website":"https://www.novartis.com/","industry":"Pharmaceuticals"},"price":114.605,"year":2024,"month":8,"day":17,"weekday":"Saturday","title":"Impact of Novartis AG's Management Team on Strategic Direction and Performance","date":"2024-08-17","url":"/posts/2024/08/17/NVS","content":[{"section":"Key Executives","text":"Novartis AG's management team consists of key executives who bring diverse expertise and experience to the organization. Some key executives include:"},{"section":"1. Vas Narasimhan - CEO","text":"Vas Narasimhan has been leading Novartis AG as CEO since 2018. His strategic vision and focus on innovation have played a crucial role in shaping the company's direction. Under his leadership, Novartis has made significant advancements in research and development, including breakthrough drug therapies."},{"section":"2. Harry Kirsch - CFO","text":"Harry Kirsch serves as the Chief Financial Officer of Novartis AG. His financial expertise and strategic decision-making skills have helped the company navigate complex financial challenges and optimize its performance. Kirsch's focus on cost management and resource allocation has contributed to improved profitability and shareholder value."},{"section":"3. Marie-France Tschudin - President, Pharmaceuticals","text":"Marie-France Tschudin leads the Pharmaceuticals division of Novartis AG. Her extensive pharmaceutical industry experience and strategic leadership have been instrumental in driving the division's growth. Tschudin's focus on portfolio optimization and successful product launches has contributed to overall revenue growth and market expansion."},{"section":"Strategic Direction","text":"The management team at Novartis AG plays a pivotal role in setting the company's strategic direction. They are responsible for identifying growth opportunities, making investments in research and development, and expanding into new markets. The team has placed a strong emphasis on innovative therapies, technological advancements, and strategic partnerships to drive long-term growth and meet the evolving needs of patients."},{"section":"Performance","text":"The management team's decisions and leadership have a direct impact on Novartis AG's performance. Through their strategic initiatives, the company has achieved significant milestones, including successful drug launches, revenue growth, and increased market share. Their focus on operational efficiency, cost management, and portfolio optimization has contributed to improved financial performance and investor confidence."},{"section":"Conclusion","text":"In conclusion, the management team of Novartis AG plays a critical role in shaping the company's strategic direction and driving its performance. With their diverse expertise and visionary leadership, they have positioned Novartis as a leading player in the pharmaceutical industry."}],"tags":["LongSignals","Long","Pharmaceuticals"],"news":[{"category":"company","date":1723819680,"headline":"Medicare Releases Negotiated Prices on 10 Expensive Drugs","id":129407571,"image":"https://media.zenfs.com/en/zacks.com/e797ee31d4bee954c41ecfac218dc795","symbol":"NVS","publisher":"Yahoo","summary":"Following negotiations between Medicare and participating drug companies, some of the world's biggest medicines will see price cuts of 38-79%. These lowered prices will be going into effect in 2026.","url":"https://finance.yahoo.com/news/medicare-releases-negotiated-prices-10-144800848.html"},{"category":"company","date":1723757400,"headline":"These 10 drugs will be cheaper after Medicare negotiations","id":129385553,"image":"https://s.yimg.com/ny/api/res/1.2/O8fEjqPSdOwPh7vRGcTY8w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2024-08/3b1e6fb0-5b26-11ef-aeff-2275f1c6f61a","symbol":"NVS","publisher":"Yahoo","summary":"For the first time ever, Medicare has successfully negotiated with pharmaceutical manufacturers to reduce the prices of ten of the most expensive prescription drugs for consumers enrolled in Medicare Part D. These new prices are set to take effect in 2026, offering discounts of nearly 79%. The list of discounted drugs includes Janssen Biotech's Stelara (JNJ), Janssen Pharmaceutical's Xarelto, Bristol Myers Squibb's Eliquis (BMY), Novartis's Entresto (NVS), Pharmacyclics's Imbruvica (ABBV), Merck's Januvia (MRK), Novo Nordisk's Fiasp (NVO), AstraZeneca's Farxiga (AZN), Immunex's Enbrel (AMGN), and Boehringer Ingelheim's Jardiance. Yahoo Finance senior health reporter Anjalee Khemlani breaks down the details. Catch the full interview with Dr. Meena Seshamani, Center for Medicare and Medicaid Services Deputy Administrator and Director of the Center for Medicare, on this topic. For more expert insight and the latest market action, click here to watch this full episode of Wealth! This post was written by Angel Smith","url":"https://finance.yahoo.com/video/10-drugs-cheaper-medicare-negotiations-213000565.html"},{"category":"company","date":1723752015,"headline":"Update: US Government Sets Out Prices of 10 Drugs in Medicare Negotiations","id":129383316,"image":"https://media.zenfs.com/en/mt_newswires_premium_news_706/a9e560796fb7d27244aee8d495d8603b","symbol":"NVS","publisher":"Yahoo","summary":"Update: US Government Sets Out Prices of 10 Drugs in Medicare Negotiations","url":"https://finance.yahoo.com/news/us-government-sets-prices-10-200015929.html"},{"category":"company","date":1723739688,"headline":"Medicare negotiates lower prices for 10 high-cost drugs","id":129378714,"image":"https://s.yimg.com/ny/api/res/1.2/bafyGSP09vSufyTk_gelHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://s.yimg.com/os/creatr-uploaded-images/2024-08/23c48880-5b18-11ef-8fdf-69e75920f0cc","symbol":"NVS","publisher":"Yahoo","summary":"Medicare has successfully negotiated drug prices with pharmaceutical manufacturers for 10 higher-priced medications. These new prices will take effect in 2026. The drugs include Janssen Biotech's Stelara, Janssen Pharm's Xarelto, Bristol Myers Squibb's (BMY) Eliquis, Novartis' (NVS) Entresto, Pharmacyclics' Imbruvica, Merck's (MRK) Januvia, Novo Nordisk's (NVO) Fiasp, AstraZeneca's (AZN) Farxiga, Immunex's Enbrel, and Boehringer Ingelheim's Jardiance. Dr. Meena Seshamani, Center for Medicare and Medicaid Services Deputy Administrator and Director of the Center for Medicare, joins Yahoo Finance health reporter Anjalee Khemlani to discuss this landmark outcome. Seshamani emphasizes the \"good faith negotiations\" that took place, considering clinical benefits and input from clinical pharmacists to drug pricing experts, all aimed at establishing fair drug pricing for all parties involved. She estimates that the new prices will save the Medicare program $6 billion, with a $1.5 billion in savings for Medicare beneficiaries who pay for prescription drugs. \"Transparency is very important and I think that has been the main goal of standing up this program,\" Seshamani told Yahoo Finance. She highlights the inclusive approach, involving patients, healthcare providers, drug plans, and companies, offering \"multiple opportunities\" for stakeholders to comment on CMS's guidance and negotiate \"access and affordability for the kind of innovative cures and therapies that people need.\" Seshamani concludes, \"I think what you see today with the result of the negotiation program really demonstrates the thoughtful, pragmatic nature that this program has been stood up and that will continue in the future.\" For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Angel Smith","url":"https://finance.yahoo.com/video/medicare-negotiates-lower-prices-10-163448713.html"},{"category":"company","date":1723737240,"headline":"Biden, Harris tout Medicare drug price reductions in joint rally appearance","id":129402173,"image":"","symbol":"NVS","publisher":"United Press International","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=c3u2qxaj1x"},{"category":"company","date":1723733344,"headline":"Big Pharma: The government revealed its list of negotiated drug prices. Here are the reactions.","id":129375968,"image":"https://s.yimg.com/ny/api/res/1.2/o0gHVmPASwuX_QQ8Xa33nQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://s.yimg.com/os/creatr-uploaded-images/2024-08/4f9462e0-5b0a-11ef-bef7-22d12ceda2e8","symbol":"NVS","publisher":"Yahoo","summary":"Medicare drug pricing has been a concern for drugmakers for the past year, as they negotiated with the government. The investor  impact appears to be muted, as Wall Street has not reacted in the hours since the reveal. Others? That's a different story.","url":"https://finance.yahoo.com/news/big-pharma-the-government-revealed-its-list-of-negotiated-drug-prices-here-are-the-reactions-144904457.html"},{"category":"company","date":1723731480,"headline":"Novartis' (NVS) Motion to Block Entresto Generic Denied: What's Next?","id":129381774,"image":"https://media.zenfs.com/en/zacks.com/f166d65586ad9d3236a947b8d942f4c9","symbol":"NVS","publisher":"Yahoo","summary":"Novartis' (NVS) efforts to ward off generic competition for its top cardiovascular drug, Entresto, face a setback.","url":"https://finance.yahoo.com/news/novartis-nvs-motion-block-entresto-141800161.html"},{"category":"company","date":1723727700,"headline":"Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth?","id":129378717,"image":"https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","symbol":"NVS","publisher":"Yahoo","summary":"Ionis (IONS) enjoys a diverse revenue stream, including numerous sources of collaborative and R\u0026D revenues. These funds enable it to invest in the development of its wholly-owned pipeline.","url":"https://finance.yahoo.com/news/ionis-ions-wholly-owned-drugs-131500752.html"},{"category":"company","date":1723722548,"headline":"Medicare to save $6B in 2026 from the first ever Part D drug pricing negotiations","id":129374870,"image":"https://s.yimg.com/ny/api/res/1.2/Y576aa_LwEyyrA99AV7OjA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04NTg-/https://s.yimg.com/os/creatr-images/2020-01/dd675f90-36a3-11ea-9fb1-e93ee8022e7a","symbol":"NVS","publisher":"Yahoo","summary":"CMS has finally revealed its first set of negotiated prices for 10 prescription drugs that will lower the government's spend on Part D drugs for seniors starting in 2026.","url":"https://finance.yahoo.com/news/medicare-to-save-6b-in-2026-from-the-first-ever-part-d-drug-pricing-negotiations-114908407.html"},{"category":"company","date":1723718880,"headline":"Healthcare Stocks Rise despite Medicare Price Cuts for Their Drugs","id":129378040,"image":"","symbol":"NVS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3601819496"},{"category":"company","date":1723715160,"headline":"NVS April 2025 Options Begin Trading","id":129381191,"image":"","symbol":"NVS","publisher":"Stock Options Channel","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3601759380"},{"category":"company","date":1723713720,"headline":"Bristol Myers, Novartis react as Medicare prices for key drugs announced","id":129378044,"image":"","symbol":"NVS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3601743911"},{"category":"company","date":1723707420,"headline":"White House says Medicare drug price negotiations will save $6 billion","id":129378046,"image":"","symbol":"NVS","publisher":"United Press International","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=f7bjfg9gwi"},{"category":"company","date":1723705200,"headline":"Biden administration announces lower prices for 10 Medicare drugs in 2026","id":129378047,"image":"","symbol":"NVS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3601625070"},{"category":"company","date":1723704360,"headline":"U.S. announces final drug prices after Medicare negotiations","id":129378048,"image":"","symbol":"NVS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3601611874"},{"category":"company","date":1723703700,"headline":"U.S. government targets $6B in savings from first Medicare drug price negotiations","id":129378049,"image":"","symbol":"NVS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3601604454"},{"category":"company","date":1723703280,"headline":"U.S. government targets $6B in saving from first Medicare drug price negotiations","id":129378050,"image":"","symbol":"NVS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3601598309"},{"category":"company","date":1723699320,"headline":"U.S. to announce prices for drugs in Medicare negotiations, NY Times says","id":129378052,"image":"","symbol":"NVS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3601551507"},{"category":"company","date":1723577688,"headline":"Tracking Tweedy, Browne Portfolio - Q2 2024 Update","id":129342100,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/953164652/image_953164652.jpg?io=getty-c-w1536","symbol":"NVS","publisher":"SeekingAlpha","summary":"Tweedy, Browne's international value fund has a non-US allocation at 85% with top non-US holdings including TotalEnergies and NestlÃ©. Learn more on TBGVX fund here.","url":"https://seekingalpha.com/article/4714221-tracking-tweedy-browne-portfolio-q2-2024-update"},{"category":"company","date":1723565636,"headline":"US judge denies initial attempt by Novartis to block generic Entresto launch","id":129342003,"image":"https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/08/shutterstock_1652254300.jpg","symbol":"NVS","publisher":"Yahoo","summary":"The court rebuffed claims by Novartis that it would experience “irreparable harm” in the absence of an injunction following MSN Pharmaceuticals’ generic roll-out.","url":"https://www.pharmaceutical-technology.com/news/us-judge-denies-initial-attempt-by-novartis-to-block-generic-entresto-launch/"},{"category":"company","date":1723551211,"headline":"Update: Novartis Unable to Block Launch of MSN Pharmaceuticals' Version of Entresto, Court Decision Shows","id":129330520,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"NVS","publisher":"Yahoo","summary":"Update: Novartis Unable to Block Launch of MSN Pharmaceuticals' Version of Entresto, Court Decision Shows","url":"https://finance.yahoo.com/news/novartis-unable-block-launch-msn-121331830.html"},{"category":"company","date":1723546860,"headline":"Starbucks picks new CEO, Baxter divests Kidney Care segment: Morning Buzz","id":129332347,"image":"","symbol":"NVS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3598895804"},{"category":"company","date":1723541700,"headline":"Judge Rules Against Novartis' Effort To Halt Generic Launch Of Its Top-Selling Heart Disease Drug","id":129348196,"image":"","symbol":"NVS","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3598796400"},{"category":"company","date":1723538340,"headline":"Novartis loses initial bid to block generic version of Entresto, Reuters reports","id":129348199,"image":"","symbol":"NVS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3598736563"},{"category":"company","date":1723485246,"headline":"Merck: Buy This Bargain Before It's Gone","id":129319064,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/971385184/image_971385184.jpg?io=getty-c-w1536","symbol":"NVS","publisher":"SeekingAlpha","summary":"Merck'sÂ stock price fell 9%Â despite beating analysts' expectations for the second quarter of 2024. See why I continue to cover MRK stock with a BuyÂ rating.","url":"https://seekingalpha.com/article/4713819-merck-buy-this-bargain-stock-before-its-gone"},{"category":"company","date":1723439700,"headline":"Fed court rules against Novartis in generic Entresto case: report","id":129348202,"image":"","symbol":"NVS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3597816948"},{"category":"company","date":1723359060,"headline":"Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value","id":129303090,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1335381149/image_1335381149.jpg?io=getty-c-w1536","symbol":"NVS","publisher":"SeekingAlpha","summary":"Ionis Pharmaceuticals has robust pipeline with over 40 drug candidates. Read why I believe IONS is a solid long-term bet despite trading at a slight premium vs peers.","url":"https://seekingalpha.com/article/4713460-ionis-pharmaceuticals-harnessing-rna-targeted-therapies-for-long-term-shareholder-value"},{"category":"company","date":1723273200,"headline":"10 High-Yield Dividend Aristocrats That Could Be Perfect For What's Coming Next","id":129284406,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/520885672/image_520885672.jpg?io=getty-c-w1536","symbol":"NVS","publisher":"SeekingAlpha","summary":"The ten high-yield, ultra-low-volatility aristocrats yield 3% and historically fall just 35% as much as the S\u0026P in downturns. Explore more details here.","url":"https://seekingalpha.com/article/4712671-10-high-yield-dividend-aristocrats-that-could-be-perfect-for-whats-coming-next"},{"category":"company","date":1723210080,"headline":"Pharma Stock Roundup: LLY, NVO, BAYRY Q2 Earnings, MRK's New Deal \u0026 Other Updates","id":129260867,"image":"https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c","symbol":"NVS","publisher":"Yahoo","summary":"Eli Lilly (LLY), Novo Nordisk (NVO) and Bayer (BAYRY) announce second-quarter results. Merck (MRK) expands existing co-development deal with partner Daiichi Sankyo.","url":"https://finance.yahoo.com/news/pharma-stock-roundup-lly-nvo-132800211.html"},{"category":"company","date":1723125167,"headline":"FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease","id":129245768,"image":"https://media.zenfs.com/en/Benzinga/012da084edb9a30e358ae885f1be16a1","symbol":"NVS","publisher":"Yahoo","summary":"On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE:NVS) Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. In December 2023, the FDA approved Fabhalta as the first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria. This indication is granted under accelerated approval based on the pre-specified interim analysis","url":"https://finance.yahoo.com/news/fda-approves-expanded-novartis-rare-135247951.html"},{"category":"company","date":1723109760,"headline":"Hold Rating on Novartis AG: Cautious Optimism for Fabhalta Amidst FDA Approval and Market Potential","id":129246619,"image":"","symbol":"NVS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3592040468"},{"category":"company","date":1723105946,"headline":"US FDA approves Novartis’ Fabhalta in IgAN treatment","id":129245770,"image":"https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/08/pt1-shutterstock_2281175947.jpg","symbol":"NVS","publisher":"Yahoo","summary":"The approval is based on interim results from the Phase III APPLAUSE-IgAN study.","url":"https://www.pharmaceutical-technology.com/news/fda-novartis-fabhalta-igan/"},{"category":"company","date":1723095060,"headline":"Novartis Gains FDA Approval for Innovative Kidney Drug","id":129246623,"image":"","symbol":"NVS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3591725956"},{"category":"company","date":1723073880,"headline":"Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)","id":129223093,"image":"https://media.zenfs.com/en/prnewswire.com/59dab5edee7d616b1b04ec7186bb8183","symbol":"NVS","publisher":"Yahoo","summary":"Novartis today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta® (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. This is generally defined as a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g1. Fabhalta specifically targets the alternative complement pathway of the immune system. When overly activated in the","url":"https://finance.yahoo.com/news/novartis-receives-fda-accelerated-approval-233800514.html"},{"category":"company","date":1723059480,"headline":"Novartis receives FDA accelerated approval for Fabhalta? (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)","id":129246624,"image":"","symbol":"NVS","publisher":"PR Newswire","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=zjz8hnsfup"},{"category":"company","date":1723012980,"headline":"Novartis receives FDA accelerated approval for Fabhalta","id":129246626,"image":"","symbol":"NVS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3590988711"},{"category":"company","date":1723003020,"headline":"Novartis gets FDA approval for Fabhalta in IgAN patients","id":129223692,"image":"","symbol":"NVS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3590633905"},{"category":"company","date":1722994080,"headline":"FDA approves Novartis' Fabhalta for additional indication","id":129209841,"image":"","symbol":"NVS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3590386184"},{"category":"company","date":1722974754,"headline":"Novartis AG (NVS): The Best Organ Transplant and Diagnosis Stock According to Street Analysts?","id":129188918,"image":"https://s.yimg.com/ny/api/res/1.2/l0DXfm34w0nXlJJiq8pUUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/aaa3d710854468813a2651c0ae6a5850","symbol":"NVS","publisher":"Yahoo","summary":"We recently compiled a list of the 10 Best Organ Transplant and Diagnosis Stocks To Buy Now. In this article, we are going to take a look at where Novartis AG (NYSE:NVS) stands against the other organ transplant and diagnosis stocks. In the dynamic landscape of healthcare, the importance of organ transplantation cannot be overstated. Transplant […]","url":"https://finance.yahoo.com/news/novartis-ag-nvs-best-organ-200554126.html"},{"category":"company","date":1722954774,"headline":"Bristol-Myers Squibb: A Potential Comeback In Healthcare","id":129178876,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/102416434/image_102416434.jpg?io=getty-c-w1536","symbol":"NVS","publisher":"SeekingAlpha","summary":"Bristol-Myers Squibb pleasantly shocked the Wall Street with its 2Q 24 financial results. See why BMY isÂ an attractive stock for long-term investors.","url":"https://seekingalpha.com/article/4711027-bristol-myers-squibb-a-potential-comeback-in-healthcare"},{"category":"company","date":1722948600,"headline":"Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs","id":129178258,"image":"","symbol":"NVS","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3588533162"},{"category":"company","date":1722944700,"headline":"Fidelity International Discovery Fund Q2 2024 Review","id":129174869,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2020375979/image_2020375979.jpg?io=getty-c-w1536","symbol":"NVS","publisher":"SeekingAlpha","summary":"For Q2 2024, Fidelity International Discovery Fund's Retail Class shares gained 1.50%, outpacing the -0.30% result of the benchmark Index. Click here for more.","url":"https://seekingalpha.com/article/4710936-fidelity-international-discovery-fund-q2-2024-review"},{"category":"company","date":1722933147,"headline":"Pipeline Moves: Novartis terminate Phase II ALS trial after benefit-risk worry","id":129170407,"image":"https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/08/shutterstock_1655333578-scaled.jpg","symbol":"NVS","publisher":"Yahoo","summary":"The Clinical Trials Arena team investigates assets in central nervous system, oncology and immunology.","url":"https://www.clinicaltrialsarena.com/features/pipeline-moves-novartis-terminate-phase-ii-als-trial-after-benefit-risk-worry/"},{"category":"company","date":1722926753,"headline":"GSK: Robust Financials, Strong Portfolio And Sector Rotation To Defensives Make It A Buy","id":129171444,"image":"","symbol":"NVS","publisher":"SeekingAlpha","summary":"","url":"https://seekingalpha.com/article/4710766-gsk-robust-financials-strong-portfolio-and-sector-rotation-to-defensives-make-it-a-buy"},{"category":"company","date":1722912420,"headline":"Tweedy Browne Funds' 2nd-Quarter Commentary: A Reflection","id":129183351,"image":"","symbol":"NVS","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3588687089"},{"category":"company","date":1722890567,"headline":"Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims","id":129158522,"image":"https://media.zenfs.com/en/reuters.com/1ff812146f995b4a7aca53060e9683e9","symbol":"NVS","publisher":"Yahoo","summary":"Novartis and Viatris were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and development.  The estate of Henrietta Lacks accused Novartis and Viatris of unlawfully profiting from the use of the \"HeLa\" cells to create drugs that have been \"integral to their market presence\" without paying or gaining permission from her estate.","url":"https://finance.yahoo.com/news/novartis-viatris-face-lawsuit-over-204247221.html"},{"category":"company","date":1722857131,"headline":"Pfizer: Tracking Well Above The Industry","id":129151531,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1487055242/image_1487055242.jpg?io=getty-c-w1536","symbol":"NVS","publisher":"SeekingAlpha","summary":"Pfizer's oncology franchise sales reached $3.96 billion in the second quarter of 2024, up 25.6% year-on-year. Learn more about PFE stock here.","url":"https://seekingalpha.com/article/4710510-pfizer-tracking-well-above-the-industry"}]}